Clinical Trials Using Zirconium Zr 89-labeled Atezolizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Zirconium Zr 89-labeled Atezolizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • 89Zr-DFO-Atezolizumab PET / CT for the Diagnosis of Locally Advanced or Metastatic Renal Cell Cancer

    This trial studies how well 89Zr-DFO-atezolizumab positron emission tomography (PET) / computed tomography (CT) works for identifying patients with kidney cancer that has spread to nearby tissues or lymph nodes (locally advanced) or has spread to other places in the body (metastatic) and to predict how the patients respond to certain immunotherapy. An immunotherapy medication called atezolizumab is tagged with zirconium-89, a radioactive atom (which is also known as an isotope). The zirconium-89 isotope is attached to atezolizumab with desferrioxamine (DFO) and this combined product is called 89Zr-DFO-atezolizumab. 89Zr-DFO-atezolizumab attaches itself to a protein on the surface of cancer cells called PD-L1. 89Zr-DFO-atezolizumab PET / CT may help doctors to know what PD-L1 levels are in the body and in cancerous tumors and how this predicts, in some patients, response to immunotherapies, and this may also help doctors to identify patients who may benefit from immunotherapy treatments.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas